Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRMD NASDAQ:GALT NASDAQ:PRTA NASDAQ:ZVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRMDCorMedix$7.95+0.4%$7.03$6.13▼$17.43$625.01M1.462.00 million shs166,553 shsGALTGalectin Therapeutics$2.09-0.9%$2.68$1.21▼$7.13$137.59M0.45337,607 shs26,756 shsPRTAProthena$11.07+5.3%$9.92$4.32▼$11.80$597.03M-0.23483,252 shs136,088 shsZVRAZevra Therapeutics$11.57+5.2%$9.73$7.16▼$13.16$683.43M0.881.03 million shs416,307 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRMDCorMedix-1.61%+4.35%+10.46%+2.99%-31.93%GALTGalectin Therapeutics-6.22%-7.05%-3.65%-24.64%+34.39%PRTAProthena-4.81%-3.78%+2.72%+19.44%+45.98%ZVRAZevra Therapeutics-2.22%+8.16%+13.64%+27.91%+46.86%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRMDCorMedix$7.95+0.4%$7.03$6.13▼$17.43$625.01M1.462.00 million shs166,553 shsGALTGalectin Therapeutics$2.09-0.9%$2.68$1.21▼$7.13$137.59M0.45337,607 shs26,756 shsPRTAProthena$11.07+5.3%$9.92$4.32▼$11.80$597.03M-0.23483,252 shs136,088 shsZVRAZevra Therapeutics$11.57+5.2%$9.73$7.16▼$13.16$683.43M0.881.03 million shs416,307 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRMDCorMedix-1.61%+4.35%+10.46%+2.99%-31.93%GALTGalectin Therapeutics-6.22%-7.05%-3.65%-24.64%+34.39%PRTAProthena-4.81%-3.78%+2.72%+19.44%+45.98%ZVRAZevra Therapeutics-2.22%+8.16%+13.64%+27.91%+46.86%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRMDCorMedix 2.63Moderate Buy$15.0088.68% UpsideGALTGalectin Therapeutics 2.00Hold$11.00426.32% UpsidePRTAProthena 2.36Hold$21.6795.67% UpsideZVRAZevra Therapeutics 2.78Moderate Buy$23.33101.64% UpsideCurrent Analyst Ratings BreakdownLatest GALT, ZVRA, CRMD, and PRTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026ZVRAZevra Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$23.00 ➝ $25.005/8/2026PRTAProthena CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/4/2026GALTGalectin Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/28/2026CRMDCorMedix Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$13.00 ➝ $14.004/28/2026CRMDCorMedix Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$19.004/28/2026CRMDCorMedix Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$13.00 ➝ $14.004/27/2026PRTAProthena Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/27/2026CRMDCorMedix Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$14.00 ➝ $15.004/27/2026CRMDCorMedix D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.004/21/2026GALTGalectin Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/16/2026ZVRAZevra Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$23.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRMDCorMedix$311.71M2.00$2.02 per share3.94$5.14 per share1.55GALTGalectin TherapeuticsN/AN/AN/AN/A($1.99) per shareN/APRTAProthena$9.68M61.58N/AN/A$5.21 per share2.13ZVRAZevra Therapeutics$106.47M6.43$0.97 per share11.89$2.75 per share4.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRMDCorMedix$163.05M$2.003.9856.79N/A52.31%52.30%29.46%5/14/2026 (Estimated)GALTGalectin Therapeutics-$30.84M-$0.48N/AN/AN/AN/AN/A-214.23%5/21/2026 (Estimated)PRTAProthena-$244.09M-$4.54N/AN/A0.39-2,520.57%-65.89%-56.00%N/AZVRAZevra Therapeutics$83.23M$1.335.818.90N/A101.58%58.24%29.08%N/ALatest GALT, ZVRA, CRMD, and PRTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026GALTGalectin Therapeutics-$0.06N/AN/AN/AN/AN/A5/14/2026Q1 2026CRMDCorMedix$0.35N/AN/AN/A$104.96 millionN/A5/6/2026Q1 2026ZVRAZevra Therapeutics$0.06$0.18+$0.12$0.60$31.96 million$36.22 million3/30/2026Q4 2025GALTGalectin Therapeutics-$0.10-$0.08+$0.02-$0.08$36.32 millionN/A3/5/2026Q4 2025CRMDCorMedix$0.86$0.16-$0.70$0.16$127.02 million$128.62 million2/19/2026Q4 2025PRTAProthena-$0.45-$0.44+$0.01-$0.40$0.67 million$0.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRMDCorMedixN/AN/AN/AN/AN/AGALTGalectin TherapeuticsN/AN/AN/AN/AN/APRTAProthenaN/AN/AN/AN/AN/AZVRAZevra TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRMDCorMedix0.362.111.94GALTGalectin TherapeuticsN/A2.422.42PRTAProthenaN/A7.727.72ZVRAZevra Therapeutics0.405.685.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRMDCorMedix34.18%GALTGalectin Therapeutics11.68%PRTAProthena97.08%ZVRAZevra Therapeutics35.03%Insider OwnershipCompanyInsider OwnershipCRMDCorMedix3.10%GALTGalectin Therapeutics52.60%PRTAProthena10.40%ZVRAZevra Therapeutics2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRMDCorMedix3078.44 million76.01 millionOptionableGALTGalectin Therapeutics965.83 million31.20 millionOptionablePRTAProthena13053.83 million48.23 millionOptionableZVRAZevra Therapeutics2059.12 million57.70 millionOptionableGALT, ZVRA, CRMD, and PRTA HeadlinesRecent News About These CompaniesResearch Analysts Offer Predictions for ZVRA Q2 Earnings2 hours ago | marketbeat.comComparing TNF Pharmaceuticals (NASDAQ:TNFA) and Zevra Therapeutics (NASDAQ:ZVRA)May 8 at 3:57 AM | americanbankingnews.comZevra Therapeutics: Q1 Earnings SnapshotMay 7 at 7:37 PM | chron.comZevra (ZVRA) Q1 2026 Earnings Call TranscriptMay 7 at 7:37 PM | fool.comIs It Too Late To Consider Zevra Therapeutics (ZVRA) After The Recent Share Price Surge?May 7 at 7:37 PM | finance.yahoo.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Q1 2026 Earnings Call TranscriptMay 7 at 8:31 AM | insidermonkey.comZevra Therapeutics Q1 Earnings Call HighlightsMay 7 at 6:06 AM | marketbeat.comZevra Therapeutics, Inc. (ZVRA) Q1 2026 Earnings Call TranscriptMay 7 at 1:01 AM | seekingalpha.comZevra Therapeutics (ZVRA) Q1 Earnings and Revenues Surpass EstimatesMay 6 at 7:35 PM | zacks.comZevra Therapeutics (NASDAQ:ZVRA) Announces Earnings ResultsMay 6 at 4:26 PM | marketbeat.comZevra Reports First Quarter 2026 Financial Results and Corporate UpdateMay 6 at 4:05 PM | globenewswire.comZevra Therapeutics (ZVRA) Expected to Announce Quarterly Earnings on WednesdayApril 29, 2026 | marketbeat.comZevra Therapeutics Announces Details for Q1 2026 Financial Results CallApril 23, 2026 | markets.businessinsider.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Average Recommendation of "Moderate Buy" from AnalystsApril 16, 2026 | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Stock Rating Upgraded by Wall Street ZenApril 11, 2026 | marketbeat.comZevra Ties NPC Testing Push To Valuation Gap And New CFOMarch 22, 2026 | finance.yahoo.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Recommendation of “Moderate Buy†by AnalystsMarch 22, 2026 | defenseworld.netDZevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)March 20, 2026 | globenewswire.comBTIG initiates coverage of Zevra Therapeutics (ZVRA) with buy recommendationMarch 16, 2026 | msn.comZevra shares jump after selling SDX portfolio for $50MMarch 16, 2026 | msn.comZevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 MillionMarch 16, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGALT, ZVRA, CRMD, and PRTA Company DescriptionsCorMedix NASDAQ:CRMD$7.95 +0.03 (+0.38%) As of 10:21 AM Eastern This is a fair market value price provided by Massive. Learn more.CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.Galectin Therapeutics NASDAQ:GALT$2.09 -0.02 (-0.95%) As of 10:02 AM EasternGalectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.Prothena NASDAQ:PRTA$11.07 +0.55 (+5.26%) As of 10:21 AM Eastern This is a fair market value price provided by Massive. Learn more.Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.Zevra Therapeutics NASDAQ:ZVRA$11.57 +0.57 (+5.20%) As of 10:21 AM Eastern This is a fair market value price provided by Massive. Learn more.Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
